|
Welcome
|
|
23 May 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ Print-friendly version ] |
| Multicenter Study Differentiated Thyroid Carcinoma |
| Link to the ClinicalTrials.gov record | Information obtained from ClinicalTrials.gov on February 23, 2012 |
| Title of trial/grant title | Multicenter Study Differentiated Thyroid Carcinoma |
| Current status of trial | Completed |
| Sponsors and collaborators | University Hospital Muenster Deutsche Krebshilfe e.V., Bonn (Germany) |
| Information provided by | University Hospital Muenster |
| ClinicalTrials.gov identifier | NCT00144079 |
| Purpose | The trial examines the clinical benefit of adjuvant external beam radiotherapy (RTx) for locally invasive differentiated carcinoma (TNM stages pT4 pN0/1/x M0/x; 5th ed. 1997) of the thyroid gland (DTC). Patients are treated with surgery (thyroidectomy and lymphadenectomy), radioiodine therapy (RIT) to ablate the thyroid remnant tissue, and TSH-suppressive L-thyroxine therapy with or without RTx after documented elimination of cervical I-131 uptake. |
| Condition(s) | Thyroid Neoplasms |
| Intervention(s) | Procedure: external beam radiotherapy |
| Phase | Phase III |
| Study type and design | Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Official title | Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma |
| Further study details | MSDS was designed as a comprehensive cohort trial with randomization and observation arms. Patients are enrolled at the time of the first ablative radioiodine therapy (RIT). Inclusion criteria are papillary or follicular DTC pT4 pN0/1/x M0/x, age between 18 (incl.) and 70 years (excl.) at the time of initial surgery, completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic residues) resection, Karnofsky index of at least 70 %, freedom from distant metastases at the time of initial radioiodine therapy (RIT), and informed patient consent. Criteria for exclusion are secondary malignancy except basalioma, pregnancy, serious general disease, serious psychiatric disorder, inability to give informed consent, previous RTx and recurrence of previous DTC. From 2003, the first inclusion criterion was changed into DTC pT3/4 pN0/1/x M0/x to reflect the 2002 revision of the TNM staging system. The treatment protocol is in accordance with current guidelines in Germany and includes total thyroidectomy (TT) with central lymphadenectomy (LNA), RIT to ablate the thyroid remnant, and TSH-suppressive therapy with L-thyroxine (TSH < 0.1 mU/l). RIT is administered under endogenous TSH-stimulation after 4 weeksâ¿¿ cessation of L-thyroxine using standard activities of 1â¿¿4, and 1â¿¿2, GBq I-131 in patients with a 24-h-I-131 uptake below 10 % and 10â¿¿20 %, resp., or individual dosimetry aiming for at least 300 Gy in the thyroid remnant. If scintigraphic I-131 uptake by the thyroid remnant persists at whole-body scintigraphy (at least 200 MBq; at least 48 h) 3 months after RIT, a second fraction of RIT is given with 4â¿¿10 GBq. Patients who consented to randomization at centers actively taking part in randomization were randomized to treatment arms A (additional adjuvant RTx) and B (no RTx) 3 months after initial RIT after confirmation of the histological diagnosis by the reference pathologist and when distant metastases had been excluded by means of serum thyroglobulin (Tg), WBS (s. a.) and a native thoracic computed tomogram (CCT). Randomization was stratified according to histological type (papillary v. follicular), nodal status (pN0/1/x), and participating center, and performed by an operator-independent randomization routine embedded in the database. The remaining patients were assigned to arms A and B by the participating centers. RTx is begun after documented elimination of cervical I-131 uptake in a I-131 WBS 3 months after the last fraction of ablative RIT. RT includes the thyroid bed (in unilateral tumors only the affected side) with a dose of 59.4 Gy and 66.6 Gy after R0 and R1 resection, resp., and the regional lymph nodes of the neck and upper mediastinum including the posterior cervical chain from the mandible and mastoid process to the tracheal bifurcation with a dose of 50.4 Gy and 54.0 Gy in pN0 and pN1/x disease, resp. Fractionation is conventional (1.8 Gy/d 5 days a week). 3-D planning according to IRCU 50 is mandatory. Patient follow-up includes, as a minimum, out-patient appointments with cervical ultrasound and measurement of serum TSH, hTG, anti-Tg antibodies and a blood count 2 and 8 months after each RIT or WBS, and a WBS (with at least 200 MBq over at least 48 h) under endogenous TSH-stimulation 3 and 12 months after ablative RIT and then at 24-month intervals. FDG-PET and other imaging modalities can be performed if needed. At each follow-up appointment, RTx toxicity is recorded according to RTOG criteria and quality of life by the QLQ-C30 questionnaire (v. 3.0 German) of the EORTC. |
| Primary outcome | time to local or distant failure cancer-related mortality |
| Secondary outcome | acute toxicity of radiotherapy (RTOG) chronic toxicity of radiotherapy (RTOG) quality of life |
| Study start | January 2000 |
| Minimum age | 18 Years |
| Maximum age | 69 Years |
| Gender | Both |
| Eligibility criteria | Inclusion Criteria: - papillary or follicular thyroid carcinoma pT4 pN0/1/x M0/x - completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic residues) resection - Karnofsky index > 70 % - freedom from distant metastases at the time of initial radioiodine therapy - informed patient consent Exclusion Criteria: - secondary malignancy except basalioma - pregnancy - serious general disease - serious psychiatric disorder - inability to give informed consent - previous RTx - recurrence of previous thyroid cancer |
| Study chairs or principal investigators | Otmar Schober, Prof MD PhD, Study Chair, Department of Nuclear Medicine, Münster University Hospital, Münster, Germany Henning Dralle, Prof MD, Study Director, Dept. of General Surgery, University Halle-Wittenberg, Halle, Germany Normann Willich, Prof MD, Study Director, Department of Radiooncology, Münster University Hospital, Münster, Germany Martin Biermann, MD, Study Director, Dept. of Nuclear Medicine, Münster University Hospital Burkhard Riemann, MD PhD, Study Director, Dept. of Nuclear Medicine, Münster University Hospital Andreas Schuck, MD PhD, Study Director, Dept. of Radiooncology, Münster University Hospital |
| Locations | Austria Department of Nuclear Medicine Linz 4010 Austria Department of Nuclear Medicine, Wien University Hospital Wien 1090 Germany Department of Nuclear Medicine, University Halle-Wittenberg Halle 06097 Germany Department of Nuclear medicine, Saarland University Homburg/Saar 66421 Germany Department of Nuclear Medicine, Cologne University Köln 50924 Germany Department of Nuclear Medicine, Münster University Hospital Münster 48129 Germany Department of Nuclear Medicine, Katharinen-Hospital Stuttgart 70174 Germany Department of Nuclear Medicine, Helios-Klinikum Wuppertal Wuppertal 44283 Germany Department of Nuclear Medicine, Würzburg University Würzburg 97080 Switzerland Department of Nuclear Medicine, Zürich University Hospital Zürich 8091 |
| Links | The trial's official website Home page of the Department of Nuclear Medicine at Münster University Hospital |
| Publications | Puskas C, Schober O. [Adjuvant percutaneous radiation of locally advanced papillary and follicular thyroid carcinoma: reflections for the necessity of a prospective multicenter study] Nuklearmedizin. 1999;38(8):328-32. Review. German. Biermann M, Schober O; Multizentrische Studie Differenziertes Schilddrusenkarzinom Studiengruppe. [How many high-risk patients with differentiated thyroid cancer need a "Tumor Center" per year?] Nuklearmedizin. 2002 Apr;41(2):61-2. German. No abstract available. Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 33:441-59, 2002 Biermann M, Pixberg M, Schuck A, Willich N, Heinecke A, Schober O. External beam radiotherapy. An evidence-based review. In: Biersack H-J, Grünwald F, eds. Thyroid cancer. Heidelberg: Springer; 139-61, 2005. |
| Results | Biermann M, Pixberg MK, Schuck A, Heinecke A, Kopcke W, Schmid KW, Dralle H, Willich N, Schober O. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin. 2003 Dec;42(6):244-50. Schuck A, Biermann M, Pixberg MK, Muller SB, Heinecke A, Schober O, Willich N. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol. 2003 Dec;179(12):832-9. Biermann M, Pixberg MK, Dorr U, Dietlein M, Schlemmer H, Grimm J, Zajic T, Nestle U, Ladner S, Sepehr-Rezai S, Rosenbaum S, Puskas C, Fostitsch P, Heinecke A, Schuck A, Willich N, Schmid KW, Dralle H, Schober O; MSDS study group. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice. Nuklearmedizin. 2005;44(6):229-34, 236-7. |
| Study ID numbers | MSDS; Deutsche Krebshilfe 70-2294 |
| Last updated | May 8, 2006 |
| Record first received | September 1, 2005 |
| ClinicalTrials.gov identifier | NCT00144079 |
| Download date | Information obtained from ClinicalTrials.gov on February 23, 2012 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | cookies | |
|
|
|
|